Hubbry Logo
PyrimethaminePyrimethamineMain
Open search
Pyrimethamine
Community hub
Pyrimethamine
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Pyrimethamine
Pyrimethamine
Pyrimethamine
View on Wikipedia
from Wikipedia

Pyrimethamine
Above: molecular structure of pyrimethamine Below: 3D representation of a pyrimethamine molecule
Clinical data
Pronunciation/ˌpɪrɪˈmɛθəmɪn/
Trade namesDaraprim, others
AHFS/Drugs.comMonograph
MedlinePlusa601050
License data
Pregnancy
category
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailabilitywell-absorbed
Protein binding87%
MetabolismLiver
Elimination half-life96 hours
ExcretionKidney
Identifiers
  • 5-(4-chlorophenyl)-6-ethylpyrimidine-2,4-diamine
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
PDB ligand
CompTox Dashboard (EPA)
ECHA InfoCard100.000.331 Edit this at Wikidata
Chemical and physical data
FormulaC12H13ClN4
Molar mass248.71 g·mol−1
3D model (JSmol)
Melting point233 to 234 °C (451 to 453 °F)
  • Clc2ccc(c1c(nc(nc1CC)N)N)cc2
  • InChI=1S/C12H13ClN4/c1-2-9-10(11(14)17-12(15)16-9)7-3-5-8(13)6-4-7/h3-6H,2H2,1H3,(H4,14,15,16,17) checkY
  • Key:WKSAUQYGYAYLPV-UHFFFAOYSA-N checkY
  (verify)

Pyrimethamine, sold under the brand name Daraprim among others, is a medication used with leucovorin (leucovorin is used to decrease side effects of pyrimethamine; it does not have intrinsic anti-parasitic activity) to treat the parasitic diseases toxoplasmosis and cystoisosporiasis.[3][4] It is also used with dapsone as a second-line option to prevent Pneumocystis jiroveci pneumonia in people with HIV/AIDS.[3] It was previously used for malaria but is no longer recommended due to resistance.[3] Pyrimethamine is taken by mouth.[3]

Common side effects include gastrointestinal upset, severe allergic reactions, and bone marrow suppression.[3] It should not be used by people with folate deficiency that has resulted in anemia.[3] There is concern that it may increase the risk of cancer.[3] While occasionally used in pregnancy it is unclear if pyrimethamine is safe for the baby.[1] Pyrimethamine is classified as a folic acid antagonist.[3] It works by inhibiting folic acid metabolism and therefore the making of DNA.[3]

Pyrimethamine was discovered in 1952 and came into medical use in 1953.[3][5] It is on the World Health Organization's List of Essential Medicines.[6] It was approved as a generic in the United States in February 2020.[7]

Medical uses

[edit]

Pyrimethamine is typically given with a sulfonamide and folinic acid.[8]

It is used for the treatment of toxoplasmosis, actinomycosis, and isosporiasis, and for the treatment and prevention of Pneumocystis jirovecii pneumonia.[3]

Toxoplasmosis

[edit]

Pyrimethamine is also used in combination with sulfadiazine to treat active toxoplasmosis. The two drugs bind the same enzymatic targets as the drugs trimethoprim and sulfamethoxazole - dihydrofolate reductase and dihydropteroate synthase, respectively.[citation needed]

Pyrimethamine has also been used in several trials to treat retinochoroiditis.[9]

Pregnancy consideration

[edit]

Pyrimethamine is labeled as pregnancy category C in the United States.[1][10] To date, not enough evidence on its risks in pregnancy or its effects on the fetus is available.[10][11]

Malaria

[edit]

It is primarily active against Plasmodium falciparum, but also against Plasmodium vivax.[12] Due to the emergence of pyrimethamine-resistant strains of P. falciparum, pyrimethamine alone is seldom used now. In combination with a long-acting sulfonamide such as sulfadiazine, it was widely used, such as in Fansidar, though resistance to this combination is increasing.[12]

Contraindications

[edit]

Pyrimethamine is contraindicated in people with folate-deficiency anaemia.[8]

Side effects

[edit]

When higher doses are used, as in the treatment of toxoplasmosis, pyrimethamine can cause gastrointestinal symptoms such as nausea, vomiting, glossitis, anorexia, and diarrhea.[11][13] A rash, which can be indicative of a hypersensitivity reaction, is also seen, particularly in combination with sulfonamides.[11] Central nervous system effects include ataxia, tremors, and seizures.[13] Hematologic side effects such as thrombocytopenia, leukopenia, and anemia can also occur.[13]

Interactions

[edit]

Other antifolate agents such as methotrexate and trimethoprim may potentiate the antifolate actions of pyrimethamine, leading to potential folate deficiency, anaemia, and other blood dyscrasias.[8]

Mechanism of action

[edit]

Pyrimethamine interferes with the regeneration of tetrahydrofolic acid from dihydrofolate by competitively inhibiting the enzyme dihydrofolate reductase.[14] Tetrahydrofolic acid is essential for DNA and RNA synthesis in many species, including protozoa.[14] It has also been found to reduce the expression of SOD1, a key protein involved in amyotrophic lateral sclerosis.[15][16]

Other medications

[edit]

Pyrimethamine is typically given with folinic acid and sulfadiazine.[10]

Mechanism of resistance

[edit]

Resistance to pyrimethamine is widespread. Mutations in the malarial gene for dihydrofolate reductase may reduce its effectiveness.[17] These mutations decrease the binding affinity between pyrimethamine and dihydrofolate reductase via loss of hydrogen bonds and steric interactions.[18]

History

[edit]
Synthesis of pyrimethamine typically begins with p-chlorophenylacetonitrile, which undergoes a condensation reaction with ethyl propionate ester; the product of this then reacts with diazomethane to form an enol ether, which reacts with free guanidine in a second condensation reaction.

Nobel Prize-winning American scientist Gertrude Elion developed the drug at Burroughs-Wellcome (now part of GlaxoSmithKline) to combat malaria.[19] Pyrimethamine has been available since 1953.[20] In 2010, GlaxoSmithKline sold the marketing rights for Daraprim to CorePharma. Impax Laboratories sought to buy CorePharma in 2014, and completed the acquisition, including Daraprim, in March 2015.[21] In August 2015, the rights were bought by Turing Pharmaceuticals.[22] Turing subsequently became infamous for a price hike controversy when it raised the price of a dose of the drug in the U.S. market from US$13.50 to US$750, a 5,500% increase.[23]

Society and culture

[edit]

Economics

[edit]

In the United States in 2015, Turing Pharmaceuticals was criticized for increasing the price 50-fold, from US$13.50 to $750 a tablet,[24] leading to a cost of $75,000 for a course of treatment reported at one hospital.[25]

United States

[edit]

In the United States, in 2015, with Turing Pharmaceuticals' acquisition of the US marketing rights for Daraprim tablets,[26] Daraprim became a single-source and specialty pharmacy item, and the price was increased.[27] The cost of a monthly course for a person on 75 mg dose rose to about $75,000/month at one hospital, or $750 per tablet while it was previously priced at $13.50.[28]

Outpatients could no longer obtain the medication from a community pharmacy, but only through a single dispensing pharmacy, Walgreens Specialty Pharmacy, and institutions could no longer order from their general wholesaler, but had to set up an account with the Daraprim Direct program.[27][29] Presentations from Retrophin, a company formerly headed by Martin Shkreli, CEO of Turing, from which Turing acquired the rights to Daraprim, suggested that a closed distribution system could prevent generic competitors from legally obtaining the drugs for the bioequivalence studies required for FDA approval of a generic drug.[29]

Shkreli defended the price hike by saying, "If there was a company that was selling an Aston Martin at the price of a bicycle, and we buy that company and we ask to charge Toyota prices, I don't think that that should be a crime."[30][31] As a result of the backlash, Shkreli hired a crisis public relations firm to help explain his fund's move.[32] Turing Pharmaceuticals announced on 24 November 2015, "that it would not reduce the list price of that drug after all", but they would offer patient assistance programs.[33] New York Times journalist Andrew Pollack noted that these programs "are standard for companies selling extremely high-priced drugs. They enable the patients to get the drug while pushing most of the costs onto insurance companies and taxpayers."[33]

The price increase was criticized by physician groups such as HIV Medicine Associates and Infectious Diseases Society of America.[34]

In 2016, a group of high school students from Sydney Grammar supported by the University of Sydney prepared pyrimethamine as an illustration that the synthesis is comparatively easy and the price-hike unjustifiable. His team produced 3.7 g for US$20, which would have been worth between US$35,000 and US$110,000 in the United States at the time.[35] Shkreli said the schoolboys were not competition, likely because the necessary bioequivalence studies require a sample of the existing medication provided directly by the company, and not simply purchased from a pharmacy, which Turing could decline to provide.[36][37] Nonetheless, the students' work was featured in The Guardian[36] and Time magazine,[38] and on ABC Australia,[35] the BBC,[37] and CNN.[39]

On 22 October 2015, Imprimis Pharmaceuticals announced it had made available compounded and customizable formulations of pyrimethamine and leucovorin in capsules to be taken by mouth starting as low as $99 for a 100-count bottle in the United States.[40] Pyrimethamine was approved as a generic in the United States in February 2020.[7]

In January 2020, the FTC filed a case against Vyera "alleging an elaborate anticompetitive scheme to preserve a monopoly for the life-saving drug, Daraprim".[41] A settlement was reached in December 2021. According to AP News, the settlement "requires Vyera and Phoenixus to provide up to $40 million in relief over 10 years to consumers who allegedly were fleeced by their actions and requires them to make Daraprim available to any potential generic competitor at the cost of producing the drug."[42] According to Law360, company executive Kevin Mulleady "agreed to a seven-year ban on working for or holding more than an 8% share in most pharmaceutical companies."[43]

Other countries

[edit]

In India, multiple combinations of generic pyrimethamine are available for a price ranging from US$0.04 to US$0.10 each (3–7 rupees).[44][45][46][47]

In the UK, the same drug is available from GSK at a cost of US$20 (£13) for 30 tablets (about $0.66 each).[48]

In Australia, the drug is available in most pharmacies at a cost of US$9.35 (A$12.99) for 50 tablets (around US$0.18 each).[49]

In Brazil, the drug is available for R$0.07 a pill, or about US$0.02.[50]

In Switzerland, the drug is available for US$9.45 (CHF9.05) for 30 tablets (around US$0.32 a piece).[51]

Research

[edit]

In 2011, researchers discovered that pyrimethamine can increase β-hexosaminidase activity, thus potentially slowing down the progression of late-onset Tay–Sachs disease.[52] It is being evaluated in clinical trials as a treatment for amyotrophic lateral sclerosis.[53]

See also

[edit]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Pyrimethamine

View on Grokipedia
from Grokipedia
Pyrimethamine is a synthetic antifolate antiparasitic drug that inhibits dihydrofolate reductase, disrupting folate metabolism and DNA synthesis in protozoan parasites such as Plasmodium species and Toxoplasma gondii. Developed in the early 1950s by Gertrude Elion and George Hitchings at Burroughs Wellcome as part of rational drug design efforts targeting folate pathways, it was introduced for medical use in 1953 and contributed to Nobel Prize recognition for its creators in 1988 for advancements in chemotherapy. It is employed primarily in combination with sulfonamides, such as sulfadiazine for toxoplasmosis in immunocompromised patients or sulfadoxine for chloroquine-resistant falciparum malaria, though widespread resistance has limited its standalone efficacy against malaria parasites. Common adverse effects include dose-dependent bone marrow suppression leading to megaloblastic anemia, leukopenia, or thrombocytopenia, necessitating folinic acid supplementation and hematologic monitoring during therapy.

Clinical Applications

Treatment and Prevention of Malaria

Pyrimethamine is employed as an adjunctive agent in the treatment of uncomplicated , particularly when combined with a such as sulfadoxine and a faster-acting schizonticide like or an derivative, to address chloroquine-resistant Plasmodium falciparum infections. The standard adult dosage for acute attacks is 50 mg daily for 2 days, while children aged 4–10 years receive 25 mg daily for 2 days; however, pyrimethamine alone is ineffective against acute episodes due to its slow and must be paired with other antimalarials. Despite its FDA approval for this indication, the Centers for Disease Control and Prevention (CDC) does not recommend pyrimethamine for treatment owing to widespread resistance and the availability of more effective artemisinin-based combination therapies (ACTs). For prevention, pyrimethamine monotherapy at 25 mg weekly for adults (with pediatric doses of 0.5 mg/kg weekly, not exceeding 25 mg) was historically used for chemoprophylaxis in non-immune individuals traveling to endemic areas, but its efficacy has been severely compromised by P. falciparum resistance to antifolate drugs, rendering it unsuitable as a primary option. In specific public health strategies, sulfadoxine-pyrimethamine (SP) combinations remain relevant for intermittent preventive treatment (IPT). For instance, the World Health Organization (WHO) endorses SP for intermittent preventive treatment in pregnancy (IPTp) in areas of moderate to high malaria transmission, administered at each antenatal visit starting from the second trimester, despite evidence of reduced protective efficacy against clinical malaria and infection prevalence due to dhps mutations conferring resistance. Similarly, seasonal malaria chemoprevention (SMC) in children aged 3–59 months involves monthly SP plus amodiaquine during peak transmission periods in the Sahel sub-region, achieving substantial reductions in malaria cases, though ongoing resistance monitoring is essential. Resistance markers, such as quintuple mutations in P. falciparum dihydrofolate reductase (dhfr) and dihydropteroate synthase (dhps) genes, correlate with diminished SP efficacy in these regimens, prompting evaluations of alternatives like dihydroartemisinin-piperaquine.

Management of Toxoplasmosis

Pyrimethamine, in combination with sulfadiazine and folinic acid (leucovorin), forms the first-line regimen for treating active toxoplasmosis caused by Toxoplasma gondii, targeting tachyzoite replication while mitigating pyrimethamine-induced folate antagonism. This combination is particularly effective for severe manifestations such as toxoplasmic encephalitis (TE) in immunocompromised patients, ocular toxoplasmosis, and congenital infections, though it primarily eradicates acute-stage parasites and may not fully eliminate dormant bradyzoites in tissue cysts, necessitating prolonged therapy or immune restoration to prevent relapse. For adults with TE or other systemic , the standard acute treatment involves a pyrimethamine of 100–200 mg orally on day 1, followed by 50–75 mg once daily, paired with sulfadiazine 1–1.5 g orally four times daily (or 75–100 mg/kg/day divided in immunocompromised cases) and 10–25 mg daily to counteract hematologic toxicity. Therapy duration is typically 6 weeks for initial episodes, with clinical response monitored via imaging and symptom resolution, followed by chronic suppressive therapy at reduced doses (pyrimethamine 25–50 mg daily plus sulfadiazine 500 mg four times daily) until CD4 recovery in patients. In sulfa-intolerant patients, alternatives include pyrimethamine plus clindamycin (300–450 mg four times daily) or atovaquone (1.5 g twice daily), maintaining supplementation. Ocular toxoplasmosis management mirrors systemic regimens but often incorporates corticosteroids for vision-threatening , with pyrimethamine dosed at 200 mg loading followed by 50 mg daily for 4–6 weeks alongside sulfadiazine. In congenital toxoplasmosis, neonatal treatment uses pyrimethamine 2 mg/kg loading then 1 mg/kg every 2–3 days, sulfadiazine 50 mg/kg twice daily, and 10 mg three times weekly for up to 12 months, guided by serial clinical and serologic assessments. Pregnancy requires caution, as pyrimethamine is contraindicated in the first trimester due to teratogenic risks including skeletal and defects, prompting alternatives like for maternal infection or delayed pyrimethamine-sulfadiazine from the second trimester if fetal infection is confirmed. Prophylaxis in high-risk immunocompromised individuals (e.g., with <100 cells/μL and positive serology) employs lower-dose pyrimethamine (25–50 mg weekly or daily) with dapsone or sulfadiazine. Overall efficacy relies on early initiation, with response rates exceeding 70% in TE cases, though resistance and incomplete cyst eradication underscore the need for adjunctive immune support.

Other Indications and Special Populations

Pyrimethamine lacks FDA approval for indications beyond toxoplasmosis and malaria, though it has been investigated in preclinical and early clinical studies for potential anticancer effects through mechanisms such as STAT3 inhibition and ubiquitin-mediated degradation of oncogenic proteins. For instance, in vitro and murine models have demonstrated antitumor activity against non-small cell lung cancer, prostate cancer, and head and neck squamous cell carcinoma, with reduced tumor growth observed at doses of 10-20 mg/kg in xenografts. Ongoing phase I/II trials, such as NCT05608044, are evaluating its efficacy in HPV-unrelated head and neck cancers prior to surgery, but clinical translation remains unproven due to limited potency compared to dedicated inhibitors like methotrexate and potential toxicity concerns. In special populations, pyrimethamine requires caution during pregnancy due to teratogenic effects observed in animal studies, including cleft palate and skeletal abnormalities at doses exceeding human equivalents; it is generally avoided in the first trimester but may be used after 18 weeks gestation for fetal toxoplasmosis, combined with and folinic acid to counteract folate depletion. Pediatric use is established for children over 2 months of age, with weight-based dosing (e.g., 0.5-1 mg/kg/day for toxoplasmosis maintenance), and specialized oral suspensions have been developed for congenital toxoplasmosis treatment to improve palatability and compliance. For elderly patients, pyrimethamine dosing does not require adjustment, but heightened monitoring for megaloblastic anemia is advised due to prevalent folate deficiency from malnutrition or concurrent medications, with leucovorin supplementation recommended prophylactically. In individuals with renal or hepatic impairment, reduced clearance may prolong exposure, necessitating dose titration and hematologic surveillance, as the drug is primarily excreted unchanged via kidneys. Immunocompromised populations, such as those with HIV, often receive pyrimethamine as secondary prophylaxis against toxoplasmosis relapse after acute therapy, typically at 25-50 mg weekly with dapsone.

Pharmacology

Mechanism of Action

Pyrimethamine acts as a competitive inhibitor of dihydrofolate reductase (DHFR), an enzyme essential for the regeneration of tetrahydrofolate (THF) from dihydrofolate (DHF) in folate metabolism. This inhibition disrupts the synthesis of thymidylate, purines, and other folate-dependent metabolites required for DNA and RNA production in rapidly dividing parasites such as Plasmodium species and Toxoplasma gondii. Parasites like Plasmodium falciparum rely on de novo folate biosynthesis because they lack the ability to uptake preformed folate from the host, making DHFR a critical target. Pyrimethamine binds to the active site of parasitic DHFR with higher affinity than to the human enzyme, primarily due to structural differences in the binding pocket, such as hydrophobic residues that favor inhibitor docking in protozoan isoforms. For instance, pyrimethamine exhibits approximately 7.6-fold greater potency against T. gondii DHFR (IC50 values in the low nanomolar range) compared to human DHFR (IC50 around 760 nM). The reversible binding of pyrimethamine to DHFR prevents the NADPH-dependent reduction of DHF to THF, leading to depletion and halted synthesis, which is particularly lethal to parasites with high replication rates. This mechanism is potentiated when pyrimethamine is combined with sulfonamides or sulfones, which inhibit upstream in the folate pathway, creating sequential blockade and synergy without altering pyrimethamine's primary DHFR targeting. While pyrimethamine shows some activity against human DHFR, its therapeutic selectivity stems from dose-dependent effects and the mammalian salvage pathway for , allowing host tolerance at concentrations.

Pharmacokinetics and Metabolism

Pyrimethamine is well absorbed from the following , with peak plasma concentrations typically achieved between 2 and 6 hours post-dose. The drug exhibits extensive binding to plasma proteins, approximately 87% in humans. It distributes widely to various tissues, including the , due to its lipophilic properties, which facilitate penetration across the blood-brain barrier. occurs primarily in the liver, though the specific enzymatic pathways remain incompletely characterized. Elimination is slow, with a plasma of approximately 96 hours, contributing to its prolonged therapeutic effect. Excretion occurs mainly via the kidneys, where 20-30% of the administered dose is eliminated unchanged, and the balance as hepatic metabolites. This renal clearance pathway underscores the need for dose adjustments in patients with impaired kidney function to avoid accumulation.

Safety Profile

Adverse Effects

Pyrimethamine, by inhibiting , frequently induces hematologic toxicities due to interference with folate-dependent DNA synthesis in rapidly dividing cells. These include , , , and , with rare but severe manifestations such as or reported in cases of prolonged high-dose therapy or inadequate supplementation. Routine co-administration of (leucovorin) at 5–25 mg daily reduces these risks by bypassing the enzymatic block, though monitoring of complete blood counts is recommended weekly during therapy exceeding 3–4 days. In a review of pyrimethamine-based regimens for , occurred in approximately 20–30% of patients, predominantly manifesting as or , though most resolved with leucovorin rescue or discontinuation. Gastrointestinal disturbances represent the most common non-hematologic effects, affecting 10–20% of users and including anorexia, , , , and , which typically emerge within the first week of treatment and are dose-related. These symptoms are often transient and managed supportively, but severe with has been noted in overdose scenarios. Neurological adverse effects, though less frequent, encompass headache, dizziness, insomnia, and irritability, occurring in under 5% of cases; seizures and respiratory depression arise primarily from acute overdosage, with the smallest reported fatal dose around 300 mg in adults. Dermatologic reactions such as rash, pruritus, and abnormal skin pigmentation are uncommon with monotherapy (incidence <2%), but hypersensitivity syndromes including erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis have been documented, particularly in fixed-dose combinations with sulfonamides like sulfadoxine, where rates of severe cutaneous reactions reached 1:5,000–1:8,000 treatments in prophylaxis settings. Rare pulmonary effects, including eosinophilic pneumonia, have also been associated with prolonged use. Overall, adverse event profiles from clinical trials indicate higher tolerability in short-term malaria prophylaxis compared to extended toxoplasmosis treatment, where cumulative doses exceed 1 g.

Contraindications and Precautions

Pyrimethamine is contraindicated in patients with known to pyrimethamine or any component of the formulation. It is also contraindicated in individuals with due to , as the drug's inhibition of exacerbates folate antagonism and can worsen hematologic suppression. Precautions are essential due to pyrimethamine's potential for dose-dependent toxicity, including , , and megaloblastic changes; complete blood counts, including platelet levels, should be monitored weekly or biweekly during therapy, particularly at doses exceeding 25 mg daily. Concomitant (leucovorin) supplementation, typically 5-15 mg daily, is recommended to counteract these effects without interfering with efficacy. Caution is advised in patients with renal impairment, where dosage reduction may be required based on clearance to prevent accumulation, as pyrimethamine is primarily excreted renally. Use in patients with (G6PD) deficiency warrants caution due to the risk of , although pyrimethamine itself is not a strong oxidant. The drug is not recommended for infants under 2 months of age or weighing less than 5 pounds, owing to immature metabolic pathways and heightened toxicity risk. In pregnancy, pyrimethamine carries an FDA C designation; have shown embryotoxicity and teratogenicity at doses of 0.4-20 mg/kg, and human data are limited, so it should be employed only when benefits outweigh potential fetal risks, preferably with . Case reports from two patients suggest possible carcinogenicity, including and non-Hodgkin's lymphoma after prolonged exposure, though causality remains unestablished and further evidence is needed.

Drug Interactions

Pyrimethamine is compatible with sulfonamides, quinine, other antimalarials, and antibiotics, often used in combination for enhanced efficacy against parasites like Plasmodium and Toxoplasma. However, concurrent administration with other antifolate agents or myelosuppressive drugs, such as sulfonamides, trimethoprim-sulfamethoxazole, proguanil, zidovudine, or methotrexate, elevates the risk of bone marrow suppression, including megaloblastic anemia, leukopenia, and thrombocytopenia. In such cases, particularly for patients with AIDS, combinations should be restricted to clinically essential scenarios, with routine monitoring of complete blood counts and supplementation of folinic acid (leucovorin) to mitigate folate deficiency without countering the drug's antiparasitic action. Additional pharmacokinetic interactions arise from pyrimethamine's inhibition of and enzymes, potentially increasing serum levels and toxicity of substrates like , erdafitinib, and eliglustat; coadministration with eliglustat is contraindicated in patients with poor metabolizer status or when combined with CYP3A inhibitors. Myelosuppressive effects are further potentiated by agents such as , ropeginterferon alfa-2b, , , and , necessitating avoidance or close hematologic surveillance. Mild hepatotoxicity has been observed with concomitant use.
Interaction CategoryExamples of Interacting DrugsClinical ConcernRecommendation
Antifolate/Myelosuppressive Additive ToxicityTrimethoprim-sulfamethoxazole, , , proguanilBone marrow suppression (e.g., , )Monitor CBC; supplement ; limit to essential use in high-risk patients like those with AIDS
CYP2C9/2D6 Inhibition, erdafitinib, eliglustatIncreased drug levels and toxicityAvoid or monitor levels; contraindicated with eliglustat in certain genotypes
Hematologic/Hepatic PotentiationDapsone, , , myelosuppression, Avoid if possible; monitor neutrophils and liver function
Pyrimethamine's long (approximately 80-120 hours) prolongs interaction risks, requiring dose adjustments or alternatives in settings, especially for immunocompromised patients. No significant interactions with food or common antiretrovirals beyond have been widely reported, but individual variability in status and activity warrants personalized assessment.

Parasite Resistance

Mechanisms of Resistance

Resistance to pyrimethamine in protozoan parasites such as and primarily arises from point mutations in the (DHFR) gene, which encodes the drug's target enzyme in the folate biosynthesis pathway. These mutations alter residues in the enzyme's , reducing pyrimethamine's binding affinity and inhibitory effect while preserving sufficient DHFR catalytic activity to support parasite replication. This target-site alteration represents the dominant mechanism, with resistance evolving under selective drug pressure through stepwise genetic changes that balance efficacy loss against fitness costs. In P. falciparum, the most prevalent human parasite, pyrimethamine resistance involves sequential DHFR mutations: the initial serine-to-asparagine substitution at codon 108 (S108N) confers moderate resistance by weakening drug-enzyme interactions; this is typically followed by asparagine-to-isoleucine at 51 (N51I) and cysteine-to-arginine at 59 (C59R), yielding intermediate resistance; high-level resistance emerges with isoleucine-to-leucine at 164 (I164L), particularly in Southeast Asian and South American strains. Compensatory mechanisms, such as amplification of the GTP cyclohydrolase I (GCH1) gene, mitigate enzymatic inefficiencies from these mutations, enhancing overall parasite fitness and resistance stability. Analogous DHFR drive resistance in T. gondii, where the is fused as a bifunctional DHFR-thymidylate (DHFR-TS). Key substitutions include tryptophan-to-arginine at position 25 (W25R), leucine-to-serine at 98 (L98S), and leucine-to-histidine at 134 (L134H); additional changes like threonine-to-asparagine at 83 (T83N), often combined with serine-to-arginine at 36 (S36R) and phenylalanine-to-serine at 245 (F245S), generate higher resistance levels in laboratory-selected strains. Unlike in plasmodia, clinical T. gondii resistance remains less widespread, though studies confirm these ' role in reducing drug susceptibility without invoking alternative pathways like efflux pumps or metabolic bypasses as primary drivers.

Clinical Implications and Strategies

Resistance to pyrimethamine in Plasmodium falciparum, primarily mediated by point mutations in the dhfr gene, has significantly diminished the efficacy of sulfadoxine-pyrimethamine (SP) combinations for treating uncomplicated , with treatment failure rates exceeding 50% in high-resistance regions of and by the early 2000s. This has contributed to prolonged parasitemia, increased severe cases, and higher , as SP monotherapy or combinations fail to achieve rapid parasite clearance compared to artemisinin-based therapies (ACTs). In pregnant women, SP resistance undermines intermittent preventive treatment in pregnancy (IPTp-SP), reducing its protective effect against placental and by up to 30% in areas with quintuple dhps mutations, prompting reevaluation of dosing regimens. For , pyrimethamine resistance, often linked to dhps mutations, manifests in treatment-refractory cases, particularly in immunocompromised patients, where standard pyrimethamine-sulfadiazine therapy yields incomplete clearance and recurrent , with in vitro studies showing values elevated over 10-fold in resistant strains. Clinical implications include higher relapse rates in cohorts, necessitating prolonged therapy or alternatives like atovaquone, though options remain limited due to the paucity of effective monotherapy substitutes. Strategies to mitigate resistance include molecular surveillance of dhfr and dhps haplotypes to guide policy, as implemented by WHO in , where prevalence of resistant quintuple mutants exceeds 90% in many IPTp sites, informing thresholds for discontinuing SP use. Combination therapies, such as SP with amodiaquine for seasonal chemoprevention (SMC), extend utility by exerting additive pressure, reducing transmission by 20-30% despite partial resistance, while avoiding monotherapy to curb selective sweeps. Rational deployment—limiting SP to preventive contexts and prioritizing ACTs for curative treatment—delays further , supported by genomic tracking of resistance spread from to since the 1980s. In toxoplasmosis, strategies emphasize folinic acid supplementation to counter host toxicity during high-dose pyrimethamine and empirical switching to clindamycin or upon failure, though prospective trials are scarce. Emerging approaches involve triple mutant dhfr inhibitors in preclinical stages to restore potency against resistant lineages.

Historical Development

Discovery and Early Synthesis

Pyrimethamine, a 2,4-diaminopyrimidine derivative, was synthesized in 1952 by and George H. Hitchings at Burroughs Wellcome Laboratories as part of a systematic program to develop antifolate compounds that selectively inhibit (DHFR) in pathogens while sparing mammalian enzymes. This approach, pioneered by Hitchings and Elion, focused on structural analogs of folic acid to disrupt synthesis in parasites, building on earlier work with and antimetabolites. The compound, initially BW-50-63, demonstrated potent activity against species in rodent models, marking it as a breakthrough in antimalarial chemotherapy amid growing resistance to and emerging synthetics like . Early synthesis of pyrimethamine proceeded via a multi-step route starting from p-chlorophenylacetonitrile, which was reacted with a diethyl ethoxymethylenemalonate intermediate to form a key precursor, followed by cyclization with to yield the ring and subsequent amination at the 4-position. This method, refined during preclinical testing, emphasized stereochemical control and yield optimization to produce the 5-(4-chlorophenyl)-6-ethylpyrimidine core, enabling scalable production for initial trials. The process highlighted the era's shift toward targeted synthesis over empirical screening, with Hitchings' team screening over 100 analogs to identify pyrimethamine's superior selectivity for parasitic DHFR over bacterial or human variants. By 1953, pyrimethamine advanced to human use following promising efficacy in suppressing P. falciparum gametocytes and schizonts, though its static action necessitated combination with fast-acting agents like sulfonamides. This early deployment underscored its role in addressing unmet needs in , with synthesis protocols evolving to support global distribution under the Daraprim.

Clinical Trials, Approval, and Initial Deployment

Pyrimethamine underwent initial synthesis and preclinical evaluation in the early 1950s at Burroughs Wellcome Laboratories by Gertrude Elion and George Hitchings, as part of targeting metabolism in parasites. Early animal studies, particularly in models, revealed its exceptional potency as a inhibitor, surpassing earlier antifolates like proguanil, which prompted rapid progression to human testing. Limited clinical trials in the 1952–1953 period involved controlled administrations to volunteers and patients in malaria-endemic settings, demonstrating effective blood schizontocidal activity against Plasmodium falciparum and P. vivax at doses of 25–50 mg weekly for prophylaxis, with minimal adverse effects beyond mild gastrointestinal upset or reversible megaloblastic changes when was co-administered. The U.S. granted approval for pyrimethamine (branded as Daraprim) in early 1953, marking it as the first antifolate specifically optimized for ; indications included chemoprophylaxis, treatment of acute attacks, and , reflecting its broad antiparasitic spectrum against apicomplexan . This expedited approval, based on efficacy data from small-scale trials and urgent needs, occurred before modern standards, prioritizing field observations over large cohorts. In the , approval for treatment followed in 1951. Initial deployment focused on malaria suppression in high-risk groups, such as travelers, expatriates, and troops in endemic regions like and , where weekly dosing regimens achieved near-complete protection in compliant users during the mid-1950s. It was integrated into control programs by organizations like the , often combined with sulfonamides to potentiate effects and mitigate monotherapy risks, yielding substantial incidence reductions in initial rollout areas; however, sporadic resistance reports surfaced by 1955 in and later spread globally, limiting standalone use within a decade. For toxoplasmosis, early adoption targeted congenital and ocular cases, with pyrimethamine-sulfadiazine regimens becoming standard by the late 1950s based on observational efficacy.

Societal and Economic Dimensions

Global Availability and Pricing Dynamics

Pyrimethamine is widely available globally as an off-patent generic medication, with production by multiple manufacturers in countries including and , facilitating access in malaria-endemic regions of , , and . Its inclusion on the World Health Organization's Model List of since at least 1977 underscores its role in programs, particularly for toxoplasmosis treatment in immunocompromised patients and as part of combination therapies like sulfadoxine-pyrimethamine for uncomplicated Plasmodium falciparum malaria. WHO-prequalified formulations, such as 500 mg sulfadoxine + 25 mg pyrimethamine tablets from Guilin Pharmaceuticals in , are distributed through international aid and national stockpiles, ensuring supply in low-resource settings despite intermittent shortages tied to funding fluctuations. In high-income regions, availability is robust but regulated. In the , generic pyrimethamine tablets (equivalent to branded Daraprim) have been approved by the FDA since 2020, distributed through specialty pharmacies for orphan indications like . European countries, including the and , offer it via national health systems with generics predominant, while in Asia-Pacific markets like , it is accessible over-the-counter or by prescription in combination forms. Supply chain disruptions, such as those during the , have occasionally affected imports, but overall stock levels remain stable due to diversified manufacturing. Pricing dynamics reflect regional economic and regulatory variances, with generics driving affordability in developing countries where tablets often cost less than $1.50 USD each, supported by compulsory licensing and local production that bypasses high research-recovery premiums. In contrast, U.S. prices for generic 25 mg tablets can exceed $50 per unit at retail pharmacies, influenced by limited domestic manufacturing, distribution markups, and incentives that prioritize rare-disease markets over volume sales. European pricing, mediated by health technology assessments and tenders, typically falls between these extremes, averaging €1-5 per tablet, while bulk procurement by organizations like the Global Fund further depresses costs in to pennies per dose in fixed-dose combinations. These disparities stem from weaker and higher rates in wealthier markets, contrasted with volume-based generics in the Global South, though parallel imports and advocacy have occasionally narrowed gaps.

The 2015 Daraprim Pricing Controversy

In August 2015, Turing Pharmaceuticals acquired the exclusive U.S. marketing rights to Daraprim, the branded formulation of pyrimethamine used to treat and other parasitic infections, and promptly raised its wholesale acquisition cost from $13.50 per 250 mg tablet to $750 per tablet, representing an increase of over 5,000 percent. This adjustment elevated the potential annual treatment cost for a 60 kg patient requiring standard dosing to approximately $336,000, exacerbating access challenges for vulnerable populations such as those with or undergoing , where can be life-threatening. Turing's CEO, , defended the pricing decision by asserting that Daraprim had been "underpriced" relative to its clinical value and that the elevated revenue would finance research and development for improved therapies, emphasizing that a full treatment course typically required fewer than 100 tablets, capping out-of-pocket costs at around $1,000 for life-saving intervention. He further argued that the prior low price discouraged innovation in the niche market, where Daraprim held orphan drug designation and faced limited generic competition due to regulatory and manufacturing hurdles. Critics, including infectious disease specialists and advocacy groups such as the Infectious Diseases of America (IDSA) and HIV Association (HIVMA), contested this rationale, highlighting the drug's decades-old status with established safety and minimal ongoing R&D needs, and warning that the hike could force hospitals to ration doses or pivot to less effective alternatives amid constrained budgets. The announcement, reported widely on September 20, 2015, ignited bipartisan congressional scrutiny and public outrage, with figures like decrying it as "outrageous" price gouging and prompting calls for antitrust investigations into Turing's market exclusivity tactics. Shkreli's subsequent media appearances, including defiant claims that he would not lower the price even if "the Turing CEO was held at gunpoint," amplified the controversy but underscored the absence of federal on off-patent drugs, allowing such hikes under existing and FDA regulations. In response, compounding pharmacies like Imprimis Pharmaceuticals introduced alternative pyrimethamine formulations by October 2015, priced at approximately $1 per dose, bypassing Turing's branded monopoly through customized preparations not subject to the same distribution restrictions. Turing eventually pledged to reduce Daraprim's price in late September amid mounting pressure, though specifics remained vague—positioned somewhere between the original and hiked levels—and tied to negotiated discounts rather than a universal rollback, preserving high list prices that persisted into subsequent years. The exposed systemic vulnerabilities in the market, where single-source pricing power incentivizes acquisitions of low-volume, high-margin generics without commensurate innovation obligations, fueling debates over regulatory reforms like mandatory generic pathways or transparency mandates, though no immediate legislative changes ensued.

Regulatory Barriers and Market Incentives

Regulatory barriers to generic entry for pyrimethamine stem primarily from the U.S. Food and Drug Administration's (FDA) requirements for abbreviated new drug applications (ANDAs), which mandate studies, current good manufacturing practices (cGMP) compliance, and stability testing even for off-patent drugs approved decades ago. For pyrimethamine, first approved in 1953, manufacturers must invest in reformulating to meet modern standards, including sourcing active pharmaceutical ingredients (APIs) that comply with FDA specifications, a process that can cost millions and take years due to limited historical data and the need for reference standards. These hurdles are exacerbated for low-volume drugs, as the FDA's pre-1962 drug efficacy reviews and subsequent updates create exclusivity for incumbent producers willing to bear compliance costs, deterring new entrants despite the absence of patents. Market incentives for pyrimethamine production remain weak due to its niche applications, primarily treating in immunocompromised and congenital infections, resulting in annual U.S. sales volumes under prescriptions and a population too small to justify generic development costs estimated at $1-5 million per ANDA. Globally, generic versions cost pennies per dose, but U.S. regulatory exclusivity and import restrictions prevent cost-effective importation, allowing sole suppliers like GlaxoSmithKline (pre-2015) and later Turing Pharmaceuticals to maintain high prices without competition. Although the Act provides incentives like tax credits for treatments, pyrimethamine's established status limits applicability to new generics, as market exclusivity applies mainly to novel indications rather than reformulations, further misaligning R&D rewards with production needs. Efforts to address these dynamics, such as FDA prioritization of generic reviews under the Generic Drug User Fee Amendments, have accelerated approvals but not overcome economic disincentives; for instance, post-2015 price hikes, only limited alternatives emerged due to restrictions on commercial products. Anti-competitive tactics, including API supply restrictions by (successor to Turing), compounded regulatory delays by complicating demonstrations, underscoring how barriers amplify monopoly rents in underserved markets.

Ongoing Research

Advances in Combination Therapies

Combination therapies involving pyrimethamine have evolved to address resistance in Plasmodium falciparum malaria, particularly through its use as sulfadoxine-pyrimethamine (SP) paired with amodiaquine in seasonal malaria chemoprevention (SMC). In regions of sub-Saharan Africa with high transmission, SP-amodiaquine monthly dosing from July to October reduced clinical malaria incidence by up to 75% in children under 5 years in Ugandan trials conducted through 2024, outperforming dihydroartemisinin-piperaquine in some metrics despite prevalent antifolate resistance markers. This approach leverages synergistic effects and lower selection pressure on individual components, with molecular surveillance showing stable dhfr/dhps mutation prevalence under community-wide deployment as of 2023. For treatment of uncomplicated malaria, SP has been evaluated in fixed-dose combinations with artemisinins, such as artesunate-SP, where recent meta-analyses indicate adequate efficacy in areas with moderate resistance, though parasite clearance rates lag behind non-antifolate regimens. Advances include triple artemisinin-based combinations incorporating SP partners to delay resistance emergence, with modeling from 2023 predicting a 2-5 year extension in therapeutic lifespan when deployed sequentially. However, WHO guidelines as of 2024 prioritize artemisinin-based therapies without SP in high-resistance zones, reserving SP combinations for prophylaxis to minimize further selection. In management, pyrimethamine-sulfadiazine remains the first-line acute therapy, with recent pediatric studies confirming its superiority in reducing Toxoplasma gondii tissue s during congenital infection when administered from the second trimester through infancy. For sulfadiazine-intolerant patients, pyrimethamine-clindamycin combinations provide comparable efficacy against in immunocompromised individuals, achieving response rates of 70-90% in cohorts per systematic reviews up to 2019, though with higher rates of gastrointestinal adverse events. Emerging resistance, evidenced by dhps-like mutations in T. gondii, prompts exploration of pyrimethamine with macrolides like , but clinical data remain limited to case series showing incomplete eradication. Resistance mitigation strategies emphasize pharmacokinetic optimization in combinations, such as co-administration with leucovorin to counteract while preserving antiparasitic activity, enabling longer courses in chronic settings. Ongoing trials integrate pyrimethamine into multi-drug regimens for ocular , reporting improved visual outcomes with adjunctive corticosteroids, though long-term relapse rates persist at 20-30%. These developments underscore a shift toward tailored, resistance-informed combinations over monotherapy, informed by genomic of parasite dhfr polymorphisms.

Emerging Applications and Resistance Mitigation

Pyrimethamine, traditionally used as an antifolate antimalarial, has garnered attention for repurposing in due to its inhibition of (DHFR) and downstream effects on cellular proliferation. Preclinical studies demonstrate its capacity to reduce tumor growth in models of various cancers, including by suppressing (STAT3) activity and inducing lethal mitophagy in cells via activation of p38/JNK/ERK pathways. In models, pyrimethamine combined with and exhibited synergistic anti-cancer effects in patient-derived stem-like cells, suggesting potential adjunctive roles in refractory tumors. Additionally, structural analogues of pyrimethamine have been investigated to enhance anti-cancer potency while minimizing off-target effects. Ongoing clinical exploration includes a phase II trial evaluating pyrimethamine as for HPV-unrelated head and neck , assessing its impact on tumor and surgical outcomes prior to standard resection. Beyond , pyrimethamine's antimicrobial properties have shown superior activity against Gardnerella biofilms associated with compared to , indicating possible expansion to non-parasitic infections. These applications leverage pyrimethamine's established safety profile from decades of antimalarial use, though dose escalation for anti-neoplastic effects requires careful monitoring for folate antagonism. Resistance to pyrimethamine in Plasmodium falciparum primarily arises from stepwise mutations in the parasite's DHFR gene, conferring high-level resistance and diminishing monotherapy efficacy. Mitigation strategies emphasize combination therapies to exploit synergistic antifolate actions and delay resistance emergence; for instance, pairing pyrimethamine with sulfonamides like sulfadoxine (as in Fansidar) targets sequential steps in folate biosynthesis, retaining partial efficacy against some resistant strains. In malaria-endemic regions, intermittent preventive treatment in pregnancy (IPTp) and seasonal malaria chemoprevention (SMC) using sulfadoxine-pyrimethamine (SP) alongside amodiaquine have proven effective in reducing prevalence, even amid moderate resistance, by slowing the spread of quintuple-mutant parasites. of molecular markers, such as dhfr/dhps quintuple mutations, informs shifts toward artemisinin-based combinations when SP efficacy wanes below therapeutic thresholds, as observed in parts of where resistance impacts protective outcomes. Emerging approaches include genomic monitoring to predict resistance trajectories and integration with non-pharmacologic interventions like to reduce selective pressure.

References

  1. https://pubchem.ncbi.nlm.nih.gov/compound/Pyrimethamine
  2. https://pmc.ncbi.nlm.nih.gov/articles/PMC89803/
  3. https://malariajournal.biomedcentral.com/articles/10.1186/s12936-019-2724-z
  4. https://www.nobelprize.org/prizes/medicine/1988/press-release/
  5. https://pmc.ncbi.nlm.nih.gov/articles/PMC3019177/
  6. https://www.ncbi.nlm.nih.gov/books/NBK548044/
  7. https://pmc.ncbi.nlm.nih.gov/articles/PMC3655235/
  8. https://pmc.ncbi.nlm.nih.gov/articles/PMC5694419/
  9. https://www.sciencedirect.com/topics/medicine-and-dentistry/pyrimethamine-sulfadiazine
  10. https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/8578s15lbl.pdf
  11. https://ahca.myflorida.com/content/download/6334/file/Daraprim_Criteria.pdf
  12. https://www.cdc.gov/malaria/php/public-health-strategy/drug-resistance.html
  13. https://pmc.ncbi.nlm.nih.gov/articles/PMC9416188/
  14. https://www.thelancet.com/journals/laninf/article/PIIS1473-3099%2825%2900219-1/fulltext
  15. https://www.cdc.gov/malaria/php/public-health-strategy/drug-strategies.html
  16. https://www.nature.com/articles/s41467-025-58326-z
  17. https://malariajournal.biomedcentral.com/articles/10.1186/s12936-022-04115-8
  18. https://www.cdc.gov/toxoplasmosis/treatment/index.html
  19. https://emedicine.medscape.com/article/229969-medication
  20. https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/toxoplasmosis
  21. https://pmc.ncbi.nlm.nih.gov/articles/PMC7033996/
  22. https://www.drugs.com/dosage/pyrimethamine.html
  23. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540558/all/Toxoplasma_gondii
  24. https://eacs.sanfordguide.com/eacs-part1/eacs-section4/ois/toxoplasma-gondii-encephalitis
  25. https://wwwnc.cdc.gov/eid/article/25/4/18-1689_article
  26. https://www.aao.org/education/current-insight/management-of-ocular-toxoplasmosis
  27. https://pmc.ncbi.nlm.nih.gov/articles/PMC12029831/
  28. https://www.merckmanuals.com/professional/infectious-diseases/extraintestinal-protozoa/toxoplasmosis
  29. https://aacrjournals.org/mct/article/18/3/541/92662/Antimalarial-Drug-Pyrimethamine-Plays-a-Dual-Role
  30. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2020.00758/full
  31. https://ar.iiarjournals.org/content/38/6/3435
  32. https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2023-02255
  33. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/008578s020lbl.pdf
  34. https://www.drugs.com/monograph/pyrimethamine.html
  35. https://www.sciencedirect.com/science/article/abs/pii/S1773224724010967
  36. https://go.drugbank.com/drugs/DB00205
  37. https://pmc.ncbi.nlm.nih.gov/articles/PMC2020854/
  38. https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b01754
  39. https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/18557slr015_fansidar_lbl.pdf
  40. https://www.sciencedirect.com/science/article/pii/S0021925821013417
  41. https://www.sciencedirect.com/topics/immunology-and-microbiology/pyrimethamine
  42. https://journals.asm.org/doi/10.1128/aac.02177-16
  43. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540462/all/Pyrimethamine
  44. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8ed8141b-e6c0-4a6b-8a08-2858c8c8bd4a
  45. https://pubmed.ncbi.nlm.nih.gov/28879584/
  46. https://pubmed.ncbi.nlm.nih.gov/16687672/
  47. https://reference.medscape.com/drug/daraprim-pyrimethamine-342668
  48. https://www.drugs.com/pregnancy/pyrimethamine-sulfadoxine.html
  49. https://mcgs.bcbsfl.com/MCG?mcgId=09-J2000-48&pv=false
  50. https://pmc.ncbi.nlm.nih.gov/articles/PMC4405445/
  51. https://pmc.ncbi.nlm.nih.gov/articles/PMC6215853/
  52. https://www.tandfonline.com/doi/full/10.1080/14787210.2021.1962291
  53. https://pmc.ncbi.nlm.nih.gov/articles/PMC5575457/
  54. https://pubmed.ncbi.nlm.nih.gov/26486699/
  55. https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2018.02587/full
  56. https://www.who.int/publications/i/item/9789240060265
  57. https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247%2824%2900115-0/fulltext
  58. https://www.thelancet.com/journals/laninf/article/PIIS1473-3099%2818%2930732-1/fulltext
  59. https://pmc.ncbi.nlm.nih.gov/articles/PMC6431062/
  60. https://www.sciencedirect.com/topics/neuroscience/pyrimethamine
  61. https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/pyrimethamine
  62. https://pubchem.ncbi.nlm.nih.gov/compound/Pyrimethamine#section=Synthesis
  63. https://pmc.ncbi.nlm.nih.gov/articles/PMC12128086/
  64. https://www.ncbi.nlm.nih.gov/books/NBK234321/
  65. https://www.lablue.com/-/media/Medical%2520Policies/2020/08/03/17/35/pyrimethamineDaraprim.pdf
  66. https://www.washingtonpost.com/opinions/why-do-drug-companies-charge-so-much-because-they-can/2015/09/25/967d3df4-6266-11e5-b38e-06883aacba64_story.html
  67. https://www.nejm.org/doi/full/10.1056/NEJMp1403340
  68. https://list.essentialmeds.org/recommendations/1154
  69. https://www.who.int/groups/expert-committee-on-selection-and-use-of-essential-medicines/essential-medicines-lists
  70. https://www.drugs.com/availability/generic-daraprim.html
  71. https://www.bbc.com/news/world-australia-38153254
  72. https://pmc.ncbi.nlm.nih.gov/articles/PMC4915805/
  73. https://www.pharmacychecker.com/pyrimethamine/
  74. https://pmc.ncbi.nlm.nih.gov/articles/PMC4904249/
  75. https://groundup.org.za/article/banal-evil-drug-pricing_3335/
  76. https://www.nytimes.com/2015/09/21/business/a-huge-overnight-increase-in-a-drugs-price-raises-protests.html
  77. https://law.stanford.edu/2015/10/05/daraprim-and-drug-pricing/
  78. https://ecampusontario.pressbooks.pub/bio16610w18/chapter/turing-pharmaceuticals-a-glimpse-into-controversial-drug-pricing/
  79. https://www.politifact.com/factchecks/2015/sep/24/martin-shkreli/fact-checking-martin-shkrelis-claim-daraprim-under/
  80. https://pmc.ncbi.nlm.nih.gov/articles/PMC4685150/
  81. https://www.npr.org/sections/health-shots/2019/12/31/792617538/a-decade-marked-by-outrage-over-drug-prices
  82. https://www.latimes.com/business/hiltzik/la-fi-mh-that-pill-that-went-from-13-50-to-750-20151023-column.html
  83. https://www.cnbc.com/2015/09/22/drug-ceo-will-lower-price-of-daraprim-after-hike-sparked-outrage.html
  84. https://academic.oup.com/jlb/article/3/1/238/1751302
  85. https://pmc.ncbi.nlm.nih.gov/articles/PMC4685151/
  86. https://www.cato.org/blog/750-generic-pill-pure-artifact-regulation
  87. https://www.drugpatentwatch.com/blog/drugs-with-no-patents-and-no-competition-heres-why/
  88. https://www.niskanencenter.org/martin-shkreli-show-us-how-regulation-drives-inequality/
  89. https://openyls.law.yale.edu/handle/20.500.13051/18130
  90. https://jamanetwork.com/journals/jama/fullarticle/2467992
  91. https://www.fdli.org/2022/06/federal-trade-commission-v-martin-shkreli/
  92. https://www.thelancet.com/journals/laninf/article/PIIS1473-3099%2824%2900746-1/abstract
  93. https://www.thelancet.com/journals/langlo/article/PIIS2214-109X%2823%2900435-7/fulltext
  94. https://pmc.ncbi.nlm.nih.gov/articles/PMC415611/
  95. https://www.sciencedirect.com/science/article/pii/S0924857923003606
  96. https://www.nature.com/articles/s41467-023-39914-3
  97. https://www.cdc.gov/toxoplasmosis/hcp/clinical-care/index.html
  98. https://pmc.ncbi.nlm.nih.gov/articles/PMC4001466/
  99. https://pmc.ncbi.nlm.nih.gov/articles/PMC5279849/
  100. https://pmc.ncbi.nlm.nih.gov/articles/PMC11267739/
  101. https://pmc.ncbi.nlm.nih.gov/articles/PMC11014785/
  102. https://pmc.ncbi.nlm.nih.gov/articles/PMC12408866/
  103. https://academic.oup.com/neuro-oncology/article/26/Supplement_5/v135/7825173
  104. https://www.sciencedirect.com/science/article/abs/pii/S0223523423009388
  105. https://academic.oup.com/jac/article-abstract/80/7/1972/8138252
  106. https://www.mdpi.com/2072-6694/14/10/2563
  107. https://www.pnas.org/doi/10.1073/pnas.0905922106
  108. https://pmc.ncbi.nlm.nih.gov/articles/PMC4925349/
  109. https://www.sciencedirect.com/science/article/abs/pii/S1471492201020852
  110. https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2021.668574/full
  111. https://www.malariaconsortium.org/resources/sulfadoxine-pyrimethamine-resistance-study
Add your contribution
Related Hubs
User Avatar
No comments yet.